secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001140361-24-045670
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma Q3 2024 net loss $198.4M; cash $235.7M; pipeline advances
-----------------------------------------------------------------------

- Net loss $198.4M ($2.11/share) for nine months ended Sept 30, 2024, vs $185.9M ($2.30/share) prior year.
- Cash $235.7M as of Sept 30; expects runway into 2026.
- R&D expenses $133.9M (down from $144.6M); G&A $76.6M (up from $51.8M) due to commercial prep.
- Completed enrollment in Phase 2 pivotal study of RP-A501 for Danon disease; dosing ongoing.
- Initiated rolling BLA for RP-L102 for Fanconi Anemia; FDA approval for KRESLADI anticipated 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036124045670/0001140361-24-045670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036124045670/ef20038212_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-045670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer